Solid Biosciences Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Solid Biosciences is a clinical-stage gene therapy company developing candidates for rare neuromuscular and cardiac diseases. It reported no product revenue and expects none for the foreseeable future.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None reported |
| Research and development expense | $18.9 million | $24.6 million; down 23.4% |
| General and administrative expense | $8.0 million | $7.4 million; up 8.0% |
| Total operating expenses | $26.9 million | $32.0 million; down 16.1% |
| Operating loss | $26.9 million | $32.0 million |
| Net loss | $24.3 million | $30.1 million |
| Net loss per share, basic and diluted | $0.64 | $1.54 |
| Net cash used in operating activities | $25.2 million | $28.0 million |
Margins are not meaningful because the company had no revenue. Net loss improved 19.2% year over year, reflecting lower operating expenses and higher interest income. Interest income was $2.7 million, versus $1.8 million.
At March 31, 2024, cash and cash equivalents were $117.6 million and available-for-sale securities were $88.5 million, totaling approximately $206.1 million, excluding $1.8 million of restricted cash. The company reported no debt outstanding; it had operating and finance lease liabilities. Current assets were $214.2 million and current liabilities were $14.3 million.
Cash from financing activities was $107.2 million, primarily from the January private placement. Investing activities used $38.5 million, largely reflecting purchases of short-term securities. The accumulated deficit was $683.1 million.
Material changes and business developments
- Research and development spending fell $5.8 million. Lower SGT-003 and SGT-001 manufacturing and nonclinical costs, and lower personnel costs, were partly offset by increased SGT-501 manufacturing and research spending.
- SGT-003 R&D expense was $1.9 million, compared with $9.1 million a year earlier; the company attributed the reduction primarily to lower manufacturing and nonclinical study costs as it prepared to dose patients. SGT-501 spending was $3.8 million, versus none in the prior-year quarter.
- On January 11, 2024, the company raised approximately $103.7 million net in a private placement of common stock and pre-funded warrants. It also received $3.1 million net from ATM sales during the quarter.
- Common shares issued and outstanding increased from 20.4 million at December 31, 2023 to 37.8 million at March 31, 2024. The pre-funded warrants cover an additional 2.7 million shares and are included in the 2024 weighted-average share count for loss-per-share purposes.
Outlook, risks and unusual items
- Management says the March 31 cash, cash equivalents and securities are expected to fund operating expenses and capital needs into 2026, based on its current operating plan and assumptions. The liquidity note separately says these resources should be sufficient for at least twelve months from issuance of the financial statements. These runway statements differ in specificity.
- The company expects continued operating losses and substantial spending as it advances SGT-003, develops other candidates and conducts clinical work. It said it anticipated dosing the first patient in the INSPIRE Duchenne trial in Q2 2024; this filing does not report that dosing as completed.
- Future funding may be needed beyond the stated runway. Additional equity financing could dilute shareholders; debt, licensing or collaboration arrangements may impose restrictions or require concessions. The company says it has no committed external source of funds.
- Key development risks include clinical safety and efficacy, trial enrollment and timing, regulatory approval, gene-therapy adverse events, manufacturing supply and consistency, reliance on third-party manufacturers, competition, and dependence on licensed intellectual property and collaborators. The filing notes a prior FDA clinical hold on the discontinued SGT-001 program.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. An outstanding $1.8 million letter of credit supports its office and laboratory lease. It expected to pay the remaining $0.1 million restructuring accrual in Q2 2024.
- Management concluded disclosure controls and procedures were effective as of March 31, 2024; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Reconcile the liquidity disclosure of “at least twelve months” with management’s MD&A estimate of funding “into 2026”; assess the assumptions and sensitivity of each estimate.
- Check whether the INSPIRE Duchenne trial began dosing in Q2 2024 and review subsequent clinical, safety, enrollment and regulatory updates.
- Monitor actual cash burn and planned spending across SGT-003, SGT-501 and other programs against the stated runway.
- Assess the dilution and potential future share count from the January 2024 financing, pre-funded warrants, ATM capacity and equity compensation plans.
- Track manufacturing readiness and clinical supply for SGT-003, including the company’s disclosed need to establish reproducible production using its manufacturing process.